title: Morganella morganii: a newly reported, rare cause of neonatal sepsis.
abstract: This case report reviews the clinical course of an 11-day-old boy who developed late-onset neonatal sepsis secondary to a rare neonatal pathogen, Morganella morganii. This gram-negative enteric bacterium, within the Enterobacteriaceae family, has most commonly been a nosocomial pathogen in debilitated, postsurgical patients. Like many other Enterobacteriaceae, M. morganii has an inducible beta-lactamase and is resistant to multiple antibiotics. When caring for neonates with culture-proven M. morganii sepsis, the authors recommend administering both a third-generation cephalosporin and an aminoglycoside to ensure that both antibiotics are bactericidal and to reduce the induction of resistance.
authors.affiliation: Department of Emergency Medicine, Medical Center of Delaware, Christiana Hospital, Newark 19718, USA. Salenp@magpage.com
authors.forename: P N
authors.initials: PN
authors.lastname: Salen
authors.forename: S
authors.initials: S
authors.lastname: Eppes
mesh_terms: D000617:Aminoglycosides; D000667:Ampicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002439:Cefotaxime / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D018432:Drug Resistance, Multiple; D004755:Enterobacteriaceae / Q000187:drug effects / Q000302:isolation & purification; D004756:Enterobacteriaceae Infections / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008826:Microbial Sensitivity Tests; D010406:Penicillins / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy / Q000382:microbiology*
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D010406:Penicillins; D000667:Ampicillin; D002439:Cefotaxime